Catalyst Pharmaceuticals Inc.

6.64-0.0500-0.75%Vol 2.73M1Y Perf 13.39%
Jun 24th, 2022 16:00 DELAYED
BID6.34 ASK6.75
Open6.74 Previous Close6.69
Pre-Market- After-Market6.64
 - -  - -%
Target Price
11.60 
Analyst Rating
Strong Buy 1.00
Potential %
74.70 
Finscreener Ranking
★★★★★     60.09
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★★     62.72
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★★★     83.92
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
47.72 
Earnings Rating
Buy
Market Cap682.46M 
Earnings Date
8th Aug 2022
Alpha0.03 Standard Deviation0.20
Beta1.29 

Today's Price Range

6.436.79

52W Range

4.818.65

5 Year PE Ratio Range

-8.8018.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
2.95%
1 Month
-3.49%
3 Months
-16.90%
6 Months
-7.52%
1 Year
13.39%
3 Years
82.92%
5 Years
133.80%
10 Years
1 092.10%

TickerPriceChg.Chg.%
CPRX6.64-0.0500-0.75
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 20220.140.12-14.29
Q04 20210.120.09-25.00
Q03 20210.100.100.00
Q02 20210.080.1475.00
Q01 20210.070.0928.57
Q04 20200.090.1122.22
Q03 20200.090.1122.22
Q02 20200.080.0912.50
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.176.25Positive
9/2022 QR0.190.00-
12/2022 FY0.67-4.29Negative
12/2023 FY0.80-5.88Negative
Next Report Date8th Aug 2022
Estimated EPS Next Report0.17
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume2.73M
Shares Outstanding102.78K
Shares Float95.03M
Trades Count11.19K
Dollar Volume18.04M
Avg. Volume1.10M
Avg. Weekly Volume1.19M
Avg. Monthly Volume1.01M
Avg. Quarterly Volume1.10M

Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock closed at 6.64 per share at the end of the most recent trading day (a -0.75% change compared to the prior day closing price) with a volume of 2.73M shares and market capitalization of 682.46M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 76 people. Catalyst Pharmaceuticals Inc. CEO is Patrick J. McEnany.

The one-year performance of Catalyst Pharmaceuticals Inc. stock is 13.39%, while year-to-date (YTD) performance is -1.92%. CPRX stock has a five-year performance of 133.8%. Its 52-week range is between 4.81 and 8.645, which gives CPRX stock a 52-week price range ratio of 47.72%

Catalyst Pharmaceuticals Inc. currently has a PE ratio of 15.90, a price-to-book (PB) ratio of 3.12, a price-to-sale (PS) ratio of 4.17, a price to cashflow ratio of 11.10, a PEG ratio of 2.32, a ROA of 20.80%, a ROC of 22.13% and a ROE of 23.17%. The company’s profit margin is 29.29%, its EBITDA margin is 39.10%, and its revenue ttm is $153.72 Million , which makes it $1.50 revenue per share.

Of the last four earnings reports from Catalyst Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.17 for the next earnings report. Catalyst Pharmaceuticals Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Catalyst Pharmaceuticals Inc. is Strong Buy (1), with a target price of $11.6, which is +74.70% compared to the current price. The earnings rating for Catalyst Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Catalyst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Catalyst Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.70, ATR14 : 0.34, CCI20 : -39.86, Chaikin Money Flow : 0.07, MACD : -0.18, Money Flow Index : 32.90, ROC : -7.39, RSI : 45.33, STOCH (14,3) : 38.89, STOCH RSI : 0.86, UO : 51.77, Williams %R : -61.11), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Catalyst Pharmaceuticals Inc. in the last 12-months were: Alicia Grande (Option Excercise at a value of $530 400), Alicia Grande (Sold 113 000 shares of value $640 779 ), Brian Elsbernd (Option Excercise at a value of $0), Charles B. O'Keeffe (Option Excercise at a value of $156 000), David S. Tierney (Option Excercise at a value of $206 600), David S. Tierney (Sold 70 000 shares of value $303 895 ), Donald A. Denkhaus (Option Excercise at a value of $268 700), Gary Ingenito (Option Excercise at a value of $0), Gary Ingenito (Sold 7 224 shares of value $50 474 ), Patrick J. McEnany (Option Excercise at a value of $936 000), Patrick J. McEnany (Sold 199 493 shares of value $1 147 646 ), Philip H. Coelho (Option Excercise at a value of $156 000), Philip H. Coelho (Sold 28 540 shares of value $157 780 ), Richard J. Daly (Option Excercise at a value of $167 500), Steven R. Miller (Option Excercise at a value of $577 200), Steven R. Miller (Sold 120 963 shares of value $694 056 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome.

CEO: Patrick J. McEnany

Telephone: +1 305 420-3200

Address: 355 Alhambra Circle, Coral Gables 33134, FL, US

Number of employees: 76

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

54%46%

Bearish Bullish

54%46%

TipRanks News for CPRX

News

Stocktwits